Equities Analysts Set Expectations for I-Mab Q1 Earnings

I-Mab (NASDAQ:NBP) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of I-Mab in a research report issued on Friday, February 6th. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. HC Wainwright also issued estimates for I-Mab’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2030 earnings at $0.14 EPS.

Several other equities research analysts have also recently weighed in on NBP. Weiss Ratings initiated coverage on shares of I-Mab in a research report on Thursday, February 5th. They issued a “sell (d-)” rating for the company. Wall Street Zen raised shares of I-Mab from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, I-Mab has a consensus rating of “Hold” and a consensus price target of $9.00.

I-Mab Price Performance

NASDAQ NBP opened at $3.42 on Monday. I-Mab has a one year low of $0.60 and a one year high of $6.79.

I-Mab (NASDAQ:NBP) last released its quarterly earnings data on Thursday, December 18th. The company reported ($0.07) earnings per share for the quarter.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.